Risk of Bleeding in Patients on Continued Dual Antiplatelet Therapy During Orthopedic Surgery

0
0
0

Risk of Bleeding in Patients on Continued Dual Antiplatelet Therapy During Orthopedic Surgery

If you or someone you know has had a coronary stent and needs orthopedic surgery—like a hip replacement, spinal fusion, or fracture repair—you’ve probably faced a terrifying trade-off: Keep taking blood-thinning dual antiplatelet therapy (DAPT, usually clopidogrel plus aspirin) to prevent deadly stent clots, or stop it to avoid surgical bleeding. A 2019 study by Chinese researchers offers critical clarity for this common dilemma: Continuing DAPT during orthopedic surgery does not raise bleeding risk—but stopping it can be fatal for the heart.

Why This Matters

Coronary stents save millions of lives each year by opening blocked heart arteries. To prevent stent thrombosis (a life-threatening clot that reblocks the stent), patients take DAPT for 6 weeks to 12 months after implantation. But orthopedic surgery—especially emergencies like hip fractures or spinal cord compression—forces a choice:

  • Continue DAPT: Risk severe surgical bleeding (e.g., spinal hematoma, wound oozing).
  • Stop DAPT: Risk stent clots, heart attacks, or death.

Until this study, few researchers had focused on how this choice plays out in orthopedic cases—where timing is often urgent (delaying hip fracture surgery by even 48 hours increases mortality, per BMJ research).

What the Study Did

San-Bao Hu from Beijing Anzhen Hospital, Capital Medical University, and colleagues analyzed data from 66 patients with coronary heart disease who underwent orthopedic surgery between 2006 and 2018. They split patients into three groups based on perioperative antiplatelet use:

  1. Group 1 (16 patients): Continued DAPT (75mg clopidogrel + 100mg aspirin daily) through surgery.
  2. Group 2 (24 patients): Took aspirin alone (100mg daily) or switched from DAPT to aspirin.
  3. Group 3 (26 patients): Stopped all antiplatelets and used low-molecular-weight heparin (a blood thinner) for 5+ days before surgery.

The team measured:

  • Intraoperative bleeding.
  • Postoperative drainage.
  • Total blood loss (via changes in hemoglobin levels, using standard formulas).
  • Cardiac complications (e.g., acute coronary syndrome, heart attacks).

Key Results: Bleeding vs. Heart Risk

The biggest surprise? Bleeding was the same across all groups. Whether patients stayed on DAPT, took aspirin alone, or switched to heparin, the amount of blood lost during surgery, after surgery, or overall was not significantly different.

But the heparin group paid a deadly price for stopping antiplatelets:

  • 3 cardiac complications, including 1 death. A 58-year-old woman with a recent stent stopped DAPT for heparin before wrist surgery—she had a heart attack 9 hours post-op and died before antiplatelets could be restarted.
  • The DAPT group had 2 cases of acute coronary syndrome (ACS, a precursor to heart attacks) but both recovered with treatment.
  • The aspirin group had 1 ACS case and 1 minor wound bleeding.

What This Means for Patients & Doctors

The study aligns with global guidelines (e.g., 2014 ACC/AHA, 2014 ESC/ESA) that warn against stopping DAPT too soon after stenting. For orthopedic surgery:

  1. Don’t stop DAPT or aspirin without a cardiologist’s OK: Stopping antiplatelets for heparin increases cardiac risk—especially if surgery is within 6 weeks of a bare-metal stent or 6 months of a drug-eluting stent.
  2. Continuing DAPT/aspirin is safe for bleeding: The study found no extra bleeding in patients who kept taking antiplatelets. For emergencies like hip fractures (where delays kill), this is life-saving.
  3. Act fast if complications arise: All ACS cases in the study improved after restarting antiplatelets or heparin. Delaying treatment—like in the 58-year-old woman—was fatal.

The Bottom Line

For stent patients needing orthopedic surgery, the balance between bleeding and clot risk favors keeping antiplatelets. Continuing DAPT or aspirin alone does not make surgery bleeding worse, but stopping antiplatelets for heparin can lead to deadly heart complications.

Every case is unique—always discuss options with a cardiologist and orthopedist. But this study offers hope: You don’t have to choose between a safe surgery and a healthy heart.

This article is based on research published in the Chinese Medical Journal (2019) by San-Bao Hu, Yong Hai, Jie-Fu Tang, Tao Liu, Bing-Xin Liang, and Bo-Qiong Xue. The study was approved by the Ethics Committee of Beijing Anzhen Hospital, with informed consent waived due to its retrospective design.

doi.org/10.1097/CM9.0000000000000186

Was this helpful?

0 / 0